MINNEAPOLIS, Oct. 27 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq:
UPI), announced today that the United
Kingdom's National Institute for Health and Clinical
Excellence (NICE) issued a guidance document titled "Percutaneous
Posterior Tibial Nerve Stimulation for Overactive Bladder
Syndrome," reinforcing the safety and effectiveness of PTNS for
overactive bladder.
"The significance of this guidance in the U.K. is a positive
statement affirming the evidence that PTNS is efficacious in
reducing the symptoms of overactive bladder and there are no major
safety concerns," said David Kaysen,
President and CEO of Uroplasty. "We will help medical directors of
U.S. private payers and Medicare carriers understand this guidance
and its significance as we continue to meet with them to expand
coverage for our Urgent® PC Neuromodulation System in the United States."
In the U.K., NICE makes recommendations to the country's
National Health Service (NHS) on new and existing medicines,
treatments and procedures with the goal of improving health and
treating and preventing poor health. A copy of the NICE guidance
may be found at www.nice.org.uk.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
medical device company that develops, manufactures and markets
innovative proprietary products for the treatment of voiding
dysfunctions. Our focus is the continued commercialization of our
Urgent PC system, which we believe is the only FDA-approved
minimally invasive nerve stimulation device designed for
office-based treatment of urinary urgency, urinary frequency and
urge incontinence – symptoms often associated with overactive
bladder.
We also offer Macroplastique Implants®, an injectable urethral
bulking agent for the treatment of adult female stress urinary
incontinence primarily due to intrinsic sphincter deficiency. For
more information on the company and its products, please visit
Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking Information
This press release contains forward-looking statements, that
reflect our best estimates regarding future events and financial
performance. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from our anticipated results. We discuss in detail the
factors that may affect the achievement of our forward-looking
statements in our Annual Report on Form 10-K filed with the SEC. In
particular, regulatory changes, including a scheduled but deferred
across-the-board reduction in Medicare reimbursement, could impact
the reimbursement received for use of our products, we may not be
able to convince all or most of the agencies that administer
government programs, or private payers, to reimburse based on the
new code, we cannot be certain that our expenditures to expand our
sales force will be justified by increased sales, and we cannot be
certain that larger competitors will not introduce products or
pharmaceuticals that target the portion of the market for which
Urgent PC is designed.
For Further
Information:
|
|
|
|
Uroplasty, Inc.
David Kaysen, President and CEO,
or
Medi Jiwani, Vice President,
CFO, and Treasurer,
952.426.6140
|
EVC Group
Doug Sherk
(Investors)
415.896.6820
Chris Gale (Media)
646.201.5431
|
|
|
|
|
|
CPT is a registered trademark of the American Medical
Association
SOURCE Uroplasty, Inc.
Copyright . 27 PR Newswire